These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 28961833)
41. Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma. Kushwaha VS; Gupta S; Husain N; Khan H; Negi MP; Jamal N; Ghatak A Cancer Biol Ther; 2015; 16(2):346-51. PubMed ID: 25756517 [TBL] [Abstract][Full Text] [Related]
42. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M; Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398 [TBL] [Abstract][Full Text] [Related]
43. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929 [TBL] [Abstract][Full Text] [Related]
44. EGFR inhibition for recurrent or metastatic HNSCC. Argiris A Lancet Oncol; 2015 May; 16(5):488-9. PubMed ID: 25892143 [No Abstract] [Full Text] [Related]
45. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Licitra L; Mesia R; Rivera F; Remenár É; Hitt R; Erfán J; Rottey S; Kawecki A; Zabolotnyy D; Benasso M; Störkel S; Senger S; Stroh C; Vermorken JB Ann Oncol; 2011 May; 22(5):1078-1087. PubMed ID: 21048039 [TBL] [Abstract][Full Text] [Related]
46. Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence. Ham JC; van Meerten E; Fiets WE; Beerepoot LV; Jeurissen FJF; Slingerland M; Jonker MA; Husson O; van der Graaf WTA; van Herpen CML Head Neck; 2020 May; 42(5):828-838. PubMed ID: 31903657 [TBL] [Abstract][Full Text] [Related]
47. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Geiger JL; Bauman JE; Gibson MK; Gooding WE; Varadarajan P; Kotsakis A; Martin D; Gutkind JS; Hedberg ML; Grandis JR; Argiris A Head Neck; 2016 Dec; 38(12):1759-1764. PubMed ID: 27232378 [TBL] [Abstract][Full Text] [Related]
48. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917 [TBL] [Abstract][Full Text] [Related]
49. Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence. Harrington KJ; Cohen EEW; Soulières D; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Swaby RF; Lin J; Ge J; Lerman N; Tourneau CL Oral Oncol; 2023 Dec; 147():106587. PubMed ID: 37925894 [TBL] [Abstract][Full Text] [Related]
50. Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC). Pectasides E; Rampias T; Sasaki C; Perisanidis C; Kouloulias V; Burtness B; Zaramboukas T; Rimm D; Fountzilas G; Psyrri A PLoS One; 2014; 9(4):e94273. PubMed ID: 24722213 [TBL] [Abstract][Full Text] [Related]
51. Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis. Saba NF; Chaudhary R; Kirtane K; Marra A; Ekpenyong A; McCook-Veal A; Schmitt NC; Gross JH; Patel MR; Remick J; Bates JE; McDonald MW; Rudra SF; Stokes WA; Biernacki M; Song X; Slebos RJC; Liu Y; Steuer CE; Shin DM; Teng Y; Chung CH Clin Cancer Res; 2024 Oct; 30(20):4601-4608. PubMed ID: 39167623 [TBL] [Abstract][Full Text] [Related]
52. Combined CD44, c-MET, and EGFR expression in p16-positive and p16-negative head and neck squamous cell carcinomas. Baschnagel AM; Tonlaar N; Eskandari M; Kumar T; Williams L; Hanna A; Pruetz BL; Wilson GD J Oral Pathol Med; 2017 Mar; 46(3):208-213. PubMed ID: 27442811 [TBL] [Abstract][Full Text] [Related]
53. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC. Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775 [TBL] [Abstract][Full Text] [Related]
54. The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma. da Costa AABA; Costa FD; Araújo DV; Camandaroba MPG; de Jesus VHF; Oliveira A; Alves ACF; Stecca C; Machado L; de Oliveira ACF; de Oliveira TB; Nicolau UR; de Lima VCC Med Oncol; 2018 Nov; 36(1):8. PubMed ID: 30478503 [TBL] [Abstract][Full Text] [Related]
55. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. Cohen EE; Rosen F; Stadler WM; Recant W; Stenson K; Huo D; Vokes EE J Clin Oncol; 2003 May; 21(10):1980-7. PubMed ID: 12743152 [TBL] [Abstract][Full Text] [Related]
56. Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype. Rampias T; Pectasides E; Prasad M; Sasaki C; Gouveris P; Dimou A; Kountourakis P; Perisanidis C; Burtness B; Zaramboukas T; Rimm D; Fountzilas G; Psyrri A Ann Oncol; 2013 Aug; 24(8):2124-31. PubMed ID: 23406730 [TBL] [Abstract][Full Text] [Related]
57. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. Pajares B; Trigo JM; Toledo MD; Álvarez M; González-Hermoso C; Rueda A; Medina JA; de Luque V; Jerez JM; Alba E BMC Cancer; 2013 Jan; 13():26. PubMed ID: 23331666 [TBL] [Abstract][Full Text] [Related]
58. A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Lee JH; Heo SG; Ahn BC; Hong MH; Cho BC; Lim SM; Kim HR Cancer Med; 2021 Oct; 10(20):7012-7020. PubMed ID: 34528763 [TBL] [Abstract][Full Text] [Related]
59. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Lim AM; Rischin D; Fisher R; Cao H; Kwok K; Truong D; McArthur GA; Young RJ; Giaccia A; Peters L; Le QT Clin Cancer Res; 2012 Jan; 18(1):301-7. PubMed ID: 22096023 [TBL] [Abstract][Full Text] [Related]
60. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. Siano M; Infante G; Resteghini C; Cau MC; Alfieri S; Bergamini C; Granata R; Miceli R; Locati L; Licitra L; Bossi P Oral Oncol; 2017 Jun; 69():33-37. PubMed ID: 28559018 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]